Asda Selects Blue Yonder’s Order Management to Accelerate its Omni-Channel Transformation
24.5.2022 13:00:00 EEST | Business Wire | Press release
Having selected Blue Yonder last year to digitally transform its end-to-end supply chain and retail operations, Asda, one of Britain’s leading retailers with a unique position in the market, is continuing its retail transformation journey with Blue Yonder by selecting Luminate® Commerce solutions to modernize its order management capabilities. Asda will also partner with Bringg, a Blue Yonder technology alliance partner and the leading delivery and fulfillment cloud platform, to make each element of the supply chain seamless, connected and orchestrated.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005263/en/
Asda consists of supercenters, superstores, and smaller supermarkets. The retailer also runs petrol filling stations and Asda Living stores, which offer its popular George clothing and home merchandise lines. The company employs more than 140,000 colleagues serving more than 16 million customers who shop in its stores and online weekly.
With Blue Yonder’s order management (OMS) microservices, Asda will be able to:
- Process orders faster to improve the customer experience.
- Provide customers with real-time inventory visibility from the beginning of the shopping experience, as well as pre-sourcing fulfillment options.
- Connect with the entire supply chain, considering the capacity to fulfill demand across any channel, at any time.
- Provide dynamic slotting options to the end customer for both home deliveries and pickup in store.
“Omni-channel is at the heart of our strategy and customer proposition, where we want to provide a great customer experience and a seamless user journey. We have been extremely impressed by Blue Yonder’s OMS microservices, which we will deploy across our grocery, clothing and general merchandise segments,” said Carl Dawson, chief information officer, Asda.
Blue Yonder’s flexible OMS microservices, powered by machine learning and artificial intelligence, will help Asda optimize the entire click-to-deliver journey, starting with an engaging customer experience through efficient order fulfillment. With Bringg, Asda will be able to optimize its last-mile operations to deliver on-time to meet customer expectations. The combination will support Asda’s home delivery service, click and collect proposition, as well as new channels such as express commerce platforms.
“Asda is leading a game-changing retail transformation focused on customer centricity, from first to last mile. We are very excited to extend our relationship with Asda into an area where we are connecting e-commerce with a true omni-channel landscape. Our modern OMS microservices are engineered to scale, perform and operate under the highest volumes seen on the market. Our OMS microservices, SaaS native, API-first components leverage the latest technology and engineering to speed up our clients’ transformations. We believe that this will help Asda to continue to modernize its business and invest in customer proposition,” said Gael Ramaen, vice president, commerce, Blue Yonder.
“The challenges and complexities of faster, more convenient and on-demand order orchestration, delivery and fulfillment are grand,” said Nikolai Avrutov, vice president Alliances, Bringg. “In order to achieve game-changing capabilities on these fronts, retailers need their technology vendors to work closely together and to relentlessly raise the bar for its mutual customers through tight collaboration and strategic co-innovation. We are proud to be doing just that with Blue Yonder for Asda.”
Additional Resources:
- Learn more about Luminate Commerce and the order management (OMS) microservices
- Learn how migrating to the cloud can digitally transform your supply chain
- Learn how Bringg’s Delivery Hub transforms your delivery orchestration with ease
About Asda Stores Ltd.
Founded in the 1960s in Yorkshire, Asda is the UK’s third largest supermarket and was acquired by the Issa Brothers and TDR Capital Ltd in 2021.
Each week more than 16 million customers visit its 640 stores - including Supercentres, Superstores, Supermarkets, Asda Living stores, and standalone petrol stations - and are served by over 140,000 colleagues. www.asda.com and www.george.com deliver to 99% of the UK’s homes and to its 538 click and collect sites across the UK.
Its main office is in Leeds, Yorkshire and its George clothing division is in Lutterworth, Leicestershire.
About Bringg
Bringg helps enterprises scale up and optimize their logistics operations with our data-led delivery and fulfillment cloud platform. Using Bringg, retailers and logistics providers can rapidly enable innovative delivery and fulfillment models that maximize the customer experience, optimize logistics operations and scale business channels for growth. Some of the world’s best-known brands in more than 50 countries use Bringg’s platform to deliver the perfect last mile experience at peak efficiency across multiple delivery models. https://www.bringg.com
About Blue Yonder
Blue Yonder is the world leader in digital supply chain and omni-channel commerce fulfillment. Our intelligent, end-to-end platform enables retailers, manufacturers and logistics providers to seamlessly predict, pivot and fulfill customer demand. With Blue Yonder, you can make more automated, profitable business decisions that deliver greater growth and re-imagined customer experiences. Blue Yonder - Fulfill your Potential™ blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005263/en/
Contact information
Blue Yonder: Marina Renneke, APR, +1 480-308-3037, marina.renneke@blueyonder.com
Bringg: Ashleigh Farber, +972542332099, ashleigh@bringg.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
